Entrada Therapeutics, Inc. (NASDAQ:TRDA) Receives $18.50 Average Target Price from Analysts

Entrada Therapeutics, Inc. (NASDAQ:TRDA) has been assigned a consensus recommendation of “Hold” from the five ratings firms that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $18.50.

TRDA has been the subject of several analyst reports. Roth Mkm set a $13.00 price objective on Entrada Therapeutics in a research report on Thursday, November 6th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Entrada Therapeutics in a report on Monday, December 29th. Guggenheim assumed coverage on shares of Entrada Therapeutics in a report on Tuesday. They set a “buy” rating and a $20.00 price objective on the stock. Finally, Oppenheimer started coverage on shares of Entrada Therapeutics in a research report on Wednesday, January 28th. They set an “outperform” rating and a $21.00 price objective for the company.

Entrada Therapeutics Stock Down 2.4%

NASDAQ:TRDA opened at $10.80 on Tuesday. Entrada Therapeutics has a 52 week low of $4.93 and a 52 week high of $13.82. The company has a fifty day simple moving average of $10.78 and a two-hundred day simple moving average of $8.02. The company has a market cap of $412.78 million, a price-to-earnings ratio of -4.34 and a beta of -0.12.

Insider Activity at Entrada Therapeutics

In related news, CFO Kory James Wentworth sold 8,910 shares of the business’s stock in a transaction dated Friday, November 21st. The stock was sold at an average price of $9.98, for a total value of $88,921.80. Following the transaction, the chief financial officer owned 110,026 shares in the company, valued at $1,098,059.48. The trade was a 7.49% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. 8.11% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Russell Investments Group Ltd. raised its stake in shares of Entrada Therapeutics by 72.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 8,808 shares of the company’s stock worth $51,000 after buying an additional 3,707 shares during the last quarter. State of Wyoming grew its holdings in Entrada Therapeutics by 130.9% in the second quarter. State of Wyoming now owns 7,575 shares of the company’s stock valued at $51,000 after purchasing an additional 4,295 shares during the period. AXQ Capital LP acquired a new stake in shares of Entrada Therapeutics during the 3rd quarter worth $67,000. Occudo Quantitative Strategies LP acquired a new stake in Entrada Therapeutics during the second quarter worth about $68,000. Finally, Inscription Capital LLC purchased a new position in Entrada Therapeutics in the third quarter valued at approximately $69,000. Institutional investors and hedge funds own 86.39% of the company’s stock.

Entrada Therapeutics Company Profile

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.